Current concepts in pharmacokinetics and their implications for clinical medicine

Wiener Klinische Wochenschrift

Volumn 113, Issue 15-16, 2001, Pages 566-572

  Müller, Markus ^a,b   Müller Zellenberg, Ulrike ^b   Hochhaus, Guenther ^b   Derendorf, Hartmut ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Clinical pharmacodynamics; Clinical pharmacokinetics; Current concepts; Drug dosing

Indexed keywords

BIOAVAILABILITY; DOSE RESPONSE; DRUG MONITORING; HUMAN; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; REVIEW; TISSUE DISTRIBUTION;

BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 0035899673     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Dost F (1953) Der Blutspiegel. Kinetik der Konzentrationsablaeufe in der Kreislaufflüssigkeit. G.Thieme, Leipzig
2. Widmark E, Tandberg J (1924) Ueber die Bedingungen für die Akkumulation indifferenter Narkotika (theoretische Berechnungen). Biochem Z 147: 358-369
3. Widmark E (1932) Die theoretischen Grundlagen und die praktische Verwendbarkeit der gerichtsmedizinischen Alkoholbestimmung. Urban und Schwarzenberg, Berlin
4. Moller E, McIntosh F, VanSlyke D (1929) Studies of urea excretion: II. Relationship between urine volume and the rate of urinary excretion by normal adults. J Clin Invest 6: 427-434
5. Hochhaus G, Barrett JS, Derendorf H (2000) Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol 40: 908-917
6. Waite AE (1894) The hermetic and alchemical writings of Aureolus Philippus Theophrastus Bombast of Hohenheim, Called Paracelsus the Great, vol 2. Elliott and Co, London
7. Kreyden OP, Geiges ML, Böni R, Burg G (2000) Botulinumtoxin: Vom Gift zum Medikament: Ein historischer Rückblick. Botulinumtoxin: from poison to medicine. A historical review. Der Hautarzt 51: 733-737
8. Fletcher AP (1995) Approaching a century and after: morbidity and potentially drug induced disease. Adverse Drug React Toxicol Rev 14: 45-64
9. Laurence DR (1981) Medicines then and now. Nature 293:13-15
10. Modell W (1967) Mass drug catastrophes and the roles of science and technology. Science 156: 346-351
11. Somerson SJ (1990) Historical perspectives on anesthetic-related cardiac arrest and resuscitation. AANA J 58: 288-295
12. Kampmeier RH (1976) Syphilis therapy: an historical perspective. J Am Vener Dis Assoc 3 (2 Pt 2): 99-108
13. Weismann K (1995) Neurosyphilis, or chronic heavy metal poisoning: Karen Blixen's lifelong disease. Sex Transm Dis 22/3: 137-144
14. Ravin JG, Ravin TB (1999) What ailed Goya? Surv Ophthalmol 44/2: 163-170
15. Haenel T (1986) Historical notes on the therapy of depression. Schweiz Med Wochenschr 116: 1652-1659
16. Jenkins JS (1995) Mozart and medicine in the eighteenth century. J R Soc Med 88/7: 408P-413P
17. Jenkins JS (1991) The medical history and death of Mozart. J R Coll Physicians Lond 25/4: 351-353
18. O'Shea JG (1988) The death of Paganini. J R Coll Physicians Lond 22/2: 104
19. Scheidt W (1967) Mercury poisoning in Mozart, Beethoven and Schubert? Med Klin 62/5: 195-196
20. Burchell HB (1983) Digitalis poisoning: historical and forensic aspects. J Am Coll Cardiol 1(2 Pt 1): 506-516
21. Ober KP (1997) The Pre-Flexnerian reports: Mark Twain's criticism of medicine in the United States. Ann Intern Med 126: 157-163
22. Rowland M, Tozer TN (1995) Clinical pharmacokinetics Concepts and applications, 3rd edn. Williams and Wilkins, Baltimore
23. Heath G, Colburn WA (2000) An evolution of drug development and clinical pharmacology during the 20th century. J Clin Pharmacol 40/9: 918-929
24. Galpin AJ, Evans WE (1993) Therapeutic drug monitoring in cancer management. Clin Chem 39 (11 Pt 2): 2419-2430
25. Ensom MH, Davis GA, Cropp CD, Ensom RJ (1998) Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 34/4: 265-279
26. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338/8: 499-505
27. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28/2: 143-160
28. Rochon PA, Gurwitz JH (1995) Drug therapy. Lancet 346 (8966): 32-36
29. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279/15: 1200-1205
30. Bates DW (1998) Drugs and adverse drug reactions: how worried should we be? JAMA 279/15: 1212
31. Bonn D (1998) Adverse drug reactions remain a major cause of death. Lancet 351 (9110): 1183
32. Ajayi F, Sun H, Perry J (2000) Adverse drug rections: a review of relevant factors. J Clin Pharmacol 40: 1093-1101
33. Schumock GT, Meek PD, Ploetz PA, Vermeulen LCPo AL, Zhang WY (1996) Economic evaluations of clinical pharmacy services-1988-1995. The Publications Committee of the American College of Clinical Pharmacy. Pharmacotherapy 16/6: 1188-1208
34. Angaran DM (1999) Clinical pharmacy saves money and lives-so what's new? Pharmacotherapy 19/12: 1352-1353
35. Gibson FM, Hyneck ML, Scherrer JJ (1982) Documented effectiveness of clinical pharmacy services. Am J Hosp Pharm 39/11: 1902-1903
36. Eldon MA (1996) Clinical pharmacokinetics during drug development. Appl Clin Trials 5: 56-64
37. Müller M, Eichler HG (1999) Tissue distribution measurements during clinical drug development. Appl Clin Trials 8: 56-60
38. Po AL, Zhang WY (1998) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351: 1829-1830
39. Sheiner LB, Tozer TN (1978) Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF (eds) Clinical pharmacology: basic principles of therapeutics. Macmillan, New York, pp 71-109
40. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051
41. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4: 655-657
42. Müller M (2000) Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 45/2-3: 255-269
43. Joukhadar C, Derendorf H, Müller M (2001) Microdialysis - a novel tool for clinical studies of ani-infectives. Eur J Clin Pharmacol (in press)
44. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40: 1399-1418
45. Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35: 401-413
46. Dalla Costa T, Nolting A, Rand K, Derendorf H (1997) Pharmacokinetic-pharmacodynamic modelling of the in vitro anti-infective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35: 426-433
47. Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD (1987) Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 41/1: 26-30
48. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG A (1989) prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7/4: 425-432
49. Jackson KA, Rosenbaum SE (1998) The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 24: 1155-1162
50. FDA (1999) Guidance document for industry: Population pharmacokinetics. US Department of Health and Human Services
51. Hanin I (1996) The Gulf War, stress and a leaky blood-brain barrier. Nat Med 2/12: 1307-1308
52. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343 (8907): 184-187
53. Müller M, Mader RM, Steiner B, Steger GG, Jansen, Gnant M, Helbich T, Jakesz R, Eichler HG, Blöchl-Daum B (1997) 5-Fluorouracil kinetics in the interstitial tumor space and clinical response in breast cancer patients. Cancer Res 57: 2598-2601
54. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG, Head DR, Relling MV, Ribeiro RC, Rubnitz JE, Kun LE, Evans WE (1998) Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92/2: 411-415
55. Front D, Israel O, Iosilevsky G, Even-Sapir E, Frenkel A, Peleg H, Steiner M, Kuten A, Kolodny G (1987) Human lung tumors: SPECT quantitation of differences in Co-57 Bleomycin uptake. Radiology 165: 129-133
56. Fischman AJ, Alpert NM, Babich JW, Rubin RH (1997) The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 29: 923-956
57. Eichler HG, Müller M (1998) Drug distribution - the forgotten relative of clinical pharmacokinetics. Clin Pharmacokinet 34: 95-99
58. Elmquist WF, Sawchuk RJ (1997) Application of microdialysis in pharmacokinetic studies. Pharm Res 14: 267-288
59. Motulsky AG (1957) Drug reactions, enzymes and biochemical genetics. JAMA 165: 835-836
60. Vesell ES, Page JG (1968) Genetic control of drug levels in man: antipyrine. Science 161 (836): 72-73
61. Vesell ES, Page JG (1968) Genetic control of drug levels in man: phenylbutazone. Science 159 (822): 1479-1480
62. Vesell ES (2000) Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40/9: 930-938
63. Carsen PE, Flanagan CL, Iokes CE, Alving AS (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124: 484-485
64. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91/23: 2001-2089
65. Mancinelli L, Cronin M, Sadee W (2000) Pharmacogenomics: The Promise of Personalized Medicine. (http://www.pharmsci.org/ScientificJournals/pharmsci/ journal/4.html) AAPS Pharmsci 2(1) article 4
66. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Dole K. Miller C, Planter M, Patrick K, Brownscheidle C, Jacobs LD (2000) Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. Drug Metab Dispos 28/8: 987-993
67. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA for The Inhaled Insulin Phase II Study Group (2001) Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357: 9253: 331
68. Santini JT, Cima MJ, Langer R (1999) A controlled-release microchip. Nature 397/6717: 335-338
69. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2001) Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18/1: 121-125
70. Torchilin VP (2000) Drug targeting. Eur J Pharm Sci [Suppl 2]: S81-91
71. Holford NH, Kimko HC, Monteleone JP, Peck CC (2000) Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40: 209-234